Dr. Reddy's inks licensing deal with Gilead for remdesivir
Dr. Reddy’s has reached an agreement with Gilead to register, manufacture and sell Gilead’s investigational drug, remdesivir, a potential treatment for COVID-19, in 127 countries including India.
Dr. Reddy’s said it will receive technology transfer from Gilead for manufacturing of remdesivir. Dr. Reddy’s also said it would need to do the manufacturing scale up and obtain regulatory approval for marketing of the drug in respective countries.
Remdesivir, an investigational antiviral therapy developed by Gilead, received Emergency Use Authorization from the Food and Drug Administration in May to treat hospitalized patients with severe COVID-19 symptoms.